Activated PI3K-delta syndrome
MONDO:0018338Also known as: APDS, senescent T-cells-lymphadenopathy-immunodeficiency syndrome due to p110delta-activating mutation
47 clinical trials for this condition and its sub-types, 5 tagged with Activated PI3K-delta syndrome itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Part of
Sub-types of Activated PI3K-delta syndrome
-
Immunodeficiency 14 6 trials
-
New drug shows promise for Long-Term control of rare immune disorders
Disease control OngoingThis study is testing the long-term safety of a drug called leniolisib in people with primary immunodeficiency disorders linked to PI3K signaling. Participants are 12 people who already took leniolisib in a previous study and may benefit from continuing it. The goal is to see if …
Phase 2 • Sponsor: Pharming Technologies B.V. • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
New hope for kids with rare immune disease: leniolisib trial launches
Disease control OngoingThis study tests a drug called leniolisib in children aged 1 to 6 years who have a rare genetic immune disorder called APDS. The drug aims to control the overactive immune system and reduce swollen lymph nodes. Researchers will monitor safety and how well the drug works over time…
Phase 3 • Sponsor: Pharming Technologies B.V. • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New hope for kids with rare immune disease: drug targets root cause
Disease control OngoingThis study tests a drug called leniolisib in children aged 4 to 11 with APDS, a rare genetic condition that causes a faulty immune system. The goal is to see if the drug is safe and can control the disease by blocking an overactive immune signal. About 15 children will take the d…
Phase 3 • Sponsor: Pharming Technologies B.V. • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC